ReviewGut and liver2021
Proton Pump Inhibitor-Related Gastric Mucosal Changes.
Review in Gut and liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07040839 (Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Multiple white flat lesions on upper endoscopy: a systematic review and meta-analysis of the association with proton pump inhibitor exposure.BMC gastroenterology · 2026Pooled it
- Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.Gut and liver · 2025Trial
- The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy forAnnals of medicine · 2022Trial
- Trial
- QT Prolongation, Ventricular Arrhythmia, and Cardiac Arrest Signals During Ceftriaxone Co-therapy with Individual Proton Pump Inhibitors: A Multidatabase Study.Cardiovascular toxicology · 2026Observational
- Long-term use of potassium-competitive acid blockers and proton pump inhibitors and the risk of metachronous gastric cancer after H. pylori eradication: a multicenter cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Aspirin Eugenol Ester Alleviates Gastric Injury by Inhibiting Ferroptosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Article
- Cobblestone-like Gastric Mucosal Changes on Endoscopy in Dogs with a History of Prolonged Proton Pump Inhibitor Therapy.Animals : an open access journal from MDPI · 2026Article
- Long term use of proton pump inhibitors and risk of stomach cancer: population based case-control study in five Nordic countries.BMJ (Clinical research ed.) · 2026Article
- Acupuncture-associated gastric mucosal repair and the EGF-EGFR-related signaling network: evidence, limitations, and prospects.Frontiers in immunology · 2026Review
- RAB25 modulates pit cell commitment by coordinating transforming growth factor-alpha secretion from gastric epithelial cells.Cell death & disease · 2025Article
- Exploration of the mechanism of the Mongolian medicine Tonglaga-5 (-5) for the treatment of n-methyl-n'-nitro-n-nitrosoguanidine-induced chronic atrophic gastritis based on network pharmacology and metabolomics.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Clinical, Endoscopic and Histologic Differences in Gastric Mucosa Between Younger and Older Adults: An Observational Study on the Aging Stomach.Medical sciences (Basel, Switzerland) · 2025Observational
- Preoperative proton pump inhibitor therapy and anastomotic leak after esophagectomy-a new perspective.Langenbeck's archives of surgery · 2025Article
- Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Relationship between gastric mucosal atrophy, cystic dilatation, and histopathological characteristics.BMC gastroenterology · 2025Article
- Risks of anti-World journal of gastroenterology · 2025Article
- Effect of proton pump inhibitor (lansoprazole) on adverse drug reactions and rational drug use in elderly patients with chronic heart failure.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are used worldwide to treat of acid-related disorders such as peptic ulcer and gastroesophageal reflux disease and to prevent gastroduodenal injuries due to nonsteroidal anti-inflammatory drugs. PPIs are the most potent inhibitors of gastric acid secretion currently available, and they are one of the most commonly prescribed classes of drugs because of their high efficacy and low toxicity. However, long-term PPI use causes histopathological changes such as parietal cell protrusion into the gland lumen, cystic dilation of gastric fundic glands, and foveolar epithelial hyperplasia. These changes can manifest on endoscopic examination as fundic gland polyps, hyperplastic polyps, multiple white and flat elevated lesions, cobblestone-like mucosa, or black spots. Clinicians must be aware of PPI-induced endoscopic features in patients with chronic long-term PPI use. Conversely, identifying patients with long-term PPI use based on their endoscopic findings is important. Recently, potassium-competitive acid blockers (P-CABs), a new class of acid suppressants that inhibit gastric acid secretion more strongly than PPIs, have recently been introduced clinically. Further long-term prospective studies on these gastric mucosal lesions in patients with either PPI or P-CAB use are required to investigate their association with histopathological changes and to establish the clinical significance of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.